Holen Sie sich die Stockscreener-App
215.70
0.56%
1.20
Handel nachbörslich:
216.00
0.30
+0.14%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$214.50
Offen:
$217
24-Stunden-Volumen:
5.38M
Relative Volume:
0.81
Marktkapitalisierung:
$381.10B
Einnahmen:
$62.82B
Nettoeinkommen (Verlust:
$3.60B
KGV:
106.39
EPS:
2.0274
Netto-Cashflow:
$19.98B
1W Leistung:
+2.52%
1M Leistung:
+7.58%
6M Leistung:
-8.71%
1J Leistung:
+18.17%
1-Tages-Spanne:
$215.70
$220.01
1-Wochen-Bereich:
$207.68
$220.01
52-Wochen-Spanne:
$181.72
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
215.70 | 378.98B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,065.00 | 928.88B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
234.34 | 557.82B | 96.36B | 21.04B | 17.80B | 8.6488 |
MRK
Merck Co Inc
|
122.41 | 286.20B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
187.03 | 294.27B | 60.48B | 10.40B | 8.05B | 3.3297 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-08 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-04 | Herabstufung | DZ Bank | Buy → Hold |
| 2025-10-14 | Herabstufung | Erste Group | Buy → Hold |
| 2025-10-01 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-08-12 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
Final trades: AbbVie, Millrose Properties, Archer-Daniels-Midland, GE Vernova and Estee Lauder - MSN
Final Trades: AbbVie, Millrose Properties, Archer-Daniels-Midland, GE Vernova and Estee Lauder - CNBC
Merck (MRK) and AbbVie (ABBV) Gain EU Panel Endorsements for New Treatments - GuruFocus
AbbVie, Merck, Astra among winners of EU drug recommendations this week - Seeking Alpha
AbbVie (ABBV) Receives Positive EMA Opinion for Maviret Approval - GuruFocus
AbbVie Announces Positive CHMP Opinion for MAVIRET® for the Treatment of Acute Hepatitis C Infection - Investing News Network
AbbVie, Novartis slash US headcount - PharmaLive
AbbVie receives EU panel backing for Maviret in acute hepatitis C - Investing.com Canada
AbbVie to present oncology pipeline data at 2026 ASCO meeting - StreetInsider
Opinion: AbbVie Is the Best Dividend King to Buy in an Increasingly Uncertain Market - The Globe and Mail
AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline - Investing News Network
AbbVie stock (US00287Y1091): focus on Humira successors after latest quarterly update - AD HOC NEWS
Allergan Aesthetics Receives Positive CHMP Opinion for Boey® for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults - Investing News Network
艾伯維公司宣佈在2026年美國臨床腫瘤學會（ASCO）年會上公佈新數據，展示其下一代腫瘤學研發管線的廣度與強勁勢頭。 - Moomoo
AbbVie (ABBV) Receives Positive EMA Opinion for Boey Approval - GuruFocus
AbbVie Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults - Yahoo Finance
Opinion: This program was meant to increase healthcare affordability. The data tell another story. - Crain's Chicago Business
Precision Trading with Abbvie Inc. (ABBV) Risk Zones - Stock Traders Daily
AbbVie Inc. (ABBV) Positioned for Long-Term Gains with IBD Pipeline Strength - Yahoo Finance
AbbVie Inc stock (US00287Y1091): new data, dividend strength and oncology focus draw investor attent - AD HOC NEWS
AbbVie stock (US00287Y1091): focus on immunology pipeline after latest data update - AD HOC NEWS
Three Dividend-Paying Healthcare Giants: Pfizer (PFE), AbbVie (ABBV), and Medtronic (MDT) Compared for 2026 - Blockonomi
High Yield Healthcare Stocks: Why Pfizer, AbbVie, and Medtronic Are Worth Watching in 2026 - CoinCentral
AbbVie stock (US00287Y1091): investors eye Skyrizi and Rinvoq momentum after latest quarterly update - AD HOC NEWS
Ichnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a First-in-Class Multispecific Immune Cells Activator Targeting Solid Tumors - GlobeNewswire Inc.
Here is what to know beyond why AbbVie Inc. (ABBV) is a trending stock - MSN
AbbVie stock (US00287Y1091): Q1 2026 earnings beat and Skyrizi, Rinvoq drive fresh momentum - AD HOC NEWS
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
UCB (UCBJY) Reports Bimzelx Success Over AbbVie's Skyrizi in Pso - GuruFocus
Top 12 Undervalued Dividend Stocks to Buy Now - Insider Monkey
UCB says Bimzelx beat AbbVie’s Skyrizi in psoriatic arthritis trial - Seeking Alpha
AbbVie (ABBV) Price Target Lowered to $235 at Evercore ISI - Insider Monkey
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock - Yahoo Finance
2 Reasons to Like ABBV and 1 to Stay Skeptical - Yahoo Finance
Neurotoxin Will Generate Booming Growth Opportunities to 2028 | AbbVie, Ipsen Group, Hugel, Inc., Medytox, Inc. etc. - openPR.com
AbbVie stock (US00287Y1091): Q1 2026 earnings highlight Skyrizi and Rinvoq as growth engines - AD HOC NEWS
AbbVie Inc stock (US00287Y1091): new oncology data and pipeline updates keep focus on long-term grow - AD HOC NEWS
Ill. Panel Sides With AbbVie In Eye-Stent Injury Suit - Law360
Here's How Neuroscience Drugs Boost AbbVie's Q1 Sales Growth - TradingView
TD Private Client Wealth LLC Sells 9,822 Shares of AbbVie Inc. $ABBV - MarketBeat
Mission Wealth Management LP Lowers Holdings in AbbVie Inc. $ABBV - MarketBeat
60,762 Shares in AbbVie Inc. $ABBV Acquired by North Dakota State Investment Board - MarketBeat
AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC - MarketBeat
AbbVie Inc. (ABBV) Stock Analysis: Unveiling a 20% Potential Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
AbbVie stock (US00287Y1091): focus on Humira erosion and Skyrizi growth after latest quarterly repor - AD HOC NEWS
AbbVie Inc stock (US00287Y1091): arthritis drug data and dividend keep the spotlight on the pharma g - AD HOC NEWS
AbbVie Inc. $ABBV Shares Sold by WealthPlan Investment Management LLC - MarketBeat
Soltis Investment Advisors LLC Acquires 12,096 Shares of AbbVie Inc. $ABBV - MarketBeat
L & S Advisors Inc Has $8.01 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Millennium Capital Advisors LLC Purchases New Shares in AbbVie Inc. $ABBV - MarketBeat
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.64%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):